Kestra Advisory Services
LCTX icon

Kestra Advisory Services’s Lineage Cell Therapeutics LCTX Stock Holding History

Kestra Advisory Services’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.6K Sell
27,847
-10,000
-26% -$11.1K ﹤0.01% 3411
2026
Q2 		$49.6K Buy
37,847
+10,000
+36% +$13.8K ﹤0.01% 3213
2026
Q1 		$44K Buy
27,847
+100
+0.4% +$169 ﹤0.01% 3065
2025
Q4 		$46.3K Buy
27,747
+17,647
+175% +$30.5K ﹤0.01% 3994
2025
Q3 		$17.1K Buy
+10,100
New +$12K ﹤0.01% 2886

Other funds holding LCTX

Defender Capital
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return
Hofer & Associates
Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return
Red Crane Wealth Management
Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Williams Jones Wealth Management
Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Kestra Advisory Services's LCTX Position: Q3 2026 in Review

Kestra Advisory Services reduced its Lineage Cell Therapeutics (LCTX) stake by 26% in Q3 2026, selling an estimated $11.1K and leaving 27,847 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3411.

Kestra Advisory Services first reported a position in LCTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $49.6K in Q2 2026. 57 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Kestra Advisory Services held 27,847 shares of Lineage Cell Therapeutics worth $26.6K as of Q3 2026.
  • Kestra Advisory Services sold 10,000 Lineage Cell Therapeutics shares in Q3 2026, an estimated $11.1K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #3411 holding.
  • Kestra Advisory Services first reported a position in Lineage Cell Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Kestra Advisory Services's Lineage Cell Therapeutics position peaked at $49.6K in Q2 2026.
  • 57 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.